SRC and atherosclerosis: The network diagram demonstrated that 7-O-galloyltricetiflavan (P15) inhibits the six bacteria by affecting the SRC, MAPK1, AKT1, HSP90AA1, HRAS, PTPN11, EGFR, LCK, RHOA, and MAPK8 targets as well as the lipid and atherosclerosis, prostate cancer and adherens junction pathways.